Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKinsey
Merck
Baxter
Moodys

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR BYDUREON PEN


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Bydureon Pen

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT04520490 ↗ Brain Activation and Satiety in Children 2 Recruiting University of Washington Phase 3 2021-01-28 Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
New Combination NCT04520490 ↗ Brain Activation and Satiety in Children 2 Recruiting Seattle Children's Hospital Phase 3 2021-01-28 Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Bydureon Pen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00103935 ↗ Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes Completed Eli Lilly and Company Phase 2 2005-02-01 Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.
NCT00103935 ↗ Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 2 2005-02-01 Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.
NCT00308139 ↗ Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) Completed AstraZeneca Phase 3 2006-04-01 A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
NCT00877890 ↗ A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) Completed Eli Lilly and Company Phase 3 2009-03-01 This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bydureon Pen

Condition Name

Condition Name for Bydureon Pen
Intervention Trials
Type 2 Diabetes 8
Type 2 Diabetes Mellitus 6
Obesity 4
Diabetes Mellitus, Type 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bydureon Pen
Intervention Trials
Diabetes Mellitus, Type 2 18
Diabetes Mellitus 14
Obesity 5
Parkinson Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bydureon Pen

Trials by Country

Trials by Country for Bydureon Pen
Location Trials
United States 135
Mexico 2
Kuwait 2
Denmark 2
Sweden 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bydureon Pen
Location Trials
Texas 11
California 8
Florida 8
New York 7
Washington 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bydureon Pen

Clinical Trial Phase

Clinical Trial Phase for Bydureon Pen
Clinical Trial Phase Trials
Phase 4 13
Phase 3 10
Phase 2 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bydureon Pen
Clinical Trial Phase Trials
Completed 23
Recruiting 6
Unknown status 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bydureon Pen

Sponsor Name

Sponsor Name for Bydureon Pen
Sponsor Trials
AstraZeneca 9
The University of Texas Health Science Center, Houston 3
Seattle Children's Hospital 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bydureon Pen
Sponsor Trials
Other 39
Industry 15
NIH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Johnson and Johnson
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.